Growth Hormone Deficiency Treatment Market Size will Grow at a Robust Pace through 2025

Growth hormone deficiency (GHD) is a medical condition characterized by insufficient production
of somatropin, a growth hormone, from the anterior pituitary gland which is responsible for the
growth and cell reproduction. Though the exact cause of growth hormone deficiency is obscure, it is
considered to be of genetic origin or also it can develop after a trauma, brain injury, due to pituitary
tumors etc. Children with growth hormone deficiency show retarded growth and sometimes delayed
puberty.
A sample of this report is available upon request @
https://www.persistencemarketresearch.com/samples/9962
Symptoms of growth hormone deficiency vary among adults and children. The predominant
symptom in children is that the child is abnormally shorter than other children of his age with or
without compromise in the cognitive intelligence while in adults, growth hormone deficiency may
lead to fatigue, tiredness, anxiety and depression.
Growth hormone deficiency is treated with growth hormone injections on daily or weekly basis
although the effects of therapy starts showing after 2-3 months of therapy.
The primary factor contributing to the growth of global growth hormone deficiency treatment
market is increasing incidence of growth hormone deficiency syndrome. Several other factors
which may cause the global growth hormone deficiency market to grow include changing lifestyle,
prevalence of other genetic disorders and incidence of GHD in adults.
However, high cost of treatment will always remain the major restraint for global growth hormone
deficiency treatment market.
The global growth hormone deficiency treatment market has been segmented on the basis of
treatment type, end user, retail sales channels and geography.
Surgeries in treatment of growth hormone deficiency treatment are rarely performed. Recombinant
human growth hormone sub-segment of pharmacological therapy treatment type is expected to hold
major share in the global growth hormone deficiency treatment market due to increased patient
compliance.
Home care settings’ end user segment occupies significant proportion of global growth hormone
deficiency treatment market owing to the nature of a therapy requiring daily dosage administration.
Introduction of new medicines such as Saizen solution is anticipated to expand the market growth
of global growth hormone deficiency treatment market over the forecast period of 2016-2026.
Geographically, the global growth hormone deficiency treatment market is segmented into five key
regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North
America is expected to contribute largest market share in global growth hormone deficiency
treatment market followed by Europe.
To view TOC of this report is available upon request @
https://www.persistencemarketresearch.com/toc/9962
Some of the major players in the global growth hormone deficiency treatment market include
Sandoz International GmbH, Sanofi Aventis, Pfizer, Novo Nordisk A/S, Teva Pharmaceutical
Industries Limited, Ranbaxy, EMD Serono, Inc., Sun Pharmaceutical Industries Ltd., Eli Lilly and
Company and others.
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a
unique collaboration of data analytics and market research methodology to help businesses achieve
optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary
approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying
real-time data collection, big data, and customer experience analytics, we deliver business
intelligence for organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: [email protected]
Web: http://www.persistencemarketresearch.com

Growth hormone deficiency (GHD) is a medical condition characterized by insufficient production of somatropin, a growth hormone, from the anterior pituitary gland which is responsible for the growth and cell reproduction.